IDH1 and Miyoshi myopathy: In this context, MGD-C9 displayed remarkable synergistic effects when combined with BTK inhibitor (pirtobrutinib) and IDH1 inhibitor (ivosidenib) in multiple MM and AML, and DLBCL cells.